Expertise in
7
conditions

Elsa Pennese

Pescara, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
Pescara, IT 

Overview

Elsa Pennese practices in Pescara, Italy. Ms. Pennese is highly rated in 7 conditions, according to our data. Her top areas of expertise are Primary Mediastinal B-Cell Lymphoma (PMBCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 36 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Pescara, Italy
Other Locations
Spirito Santo, Italy
Rimini, Italy
Brescia, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Gemcitabine, Dexamethasone, Cisplatin
Study Phase: Phase 2/Phase 3
FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role: an International Multicenter Retrospective Analysis
FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role: an International Multicenter Retrospective Analysis
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2026
Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.
Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.
Enrollment Status: Active_not_recruiting
Publish Date: January 05, 2026
Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Ibrutinib in Combination to Rituximab-CHOP Followed by Ibrutinib Maintenance in Untreated Patients With Activated-B-Cell (ABC)-DLBCL at Intermediate-high and High Risk (IPI ≥2)
Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Ibrutinib in Combination to Rituximab-CHOP Followed by Ibrutinib Maintenance in Untreated Patients With Activated-B-Cell (ABC)-DLBCL at Intermediate-high and High Risk (IPI ≥2)
Enrollment Status: Active_not_recruiting
Publish Date: December 24, 2025
Intervention Type: Drug
Study Drug: Ibrutinib
Study Phase: Phase 2
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi.
Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi.
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug
Study Phase: Phase 3
Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients With Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)
Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients With Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)
Enrollment Status: Completed
Publish Date: January 30, 2025
Intervention Type: Drug, Radiation
Study Drugs: Rituximab, Methotrexate, Procarbazine, Lenalidomide, Temozolomide
Study Phase: Phase 2
Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.
Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.
Enrollment Status: Completed
Publish Date: June 11, 2021
Intervention Type: Drug
Study Drug: Eltrombopag
Study Phase: Phase 2
View 6 Less Clinical Trials

36 Total Publications

Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy.
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy.
Journal: Leukemia & lymphoma
Published: January 29, 2026

Frequently Asked Questions about Elsa Pennese

Is Elsa Pennese a top-rated expert for Primary Mediastinal B-Cell Lymphoma (PMBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Elsa Pennese is classified as an Distinguished expert for Primary Mediastinal B-Cell Lymphoma (PMBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Elsa Pennese participate in research or clinical trials?

Yes. Elsa Pennese has published 36 articles and abstracts on conditions like Primary Mediastinal B-Cell Lymphoma (PMBCL). You can view a list of Elsa Pennese's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Pennese's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile